ערך בספרים למניה: Amicus Therapeutics Inc (FOLD)

The visualization of Amicus Therapeutics (FOLD) market value on the GURU.Markets platform confirms the resilience of a business protected by insurmountable patent barriers and strict FDA oversight. Amicus Therapeutics (FOLD) revenues are based on the commercialization of advanced therapies for Pompe and Fabry diseases, with the indicator standing at 0.88. The nature of rare pathologies renders demand independent of market cycles, tying success to clinical trial results.

Amicus Therapeutics (FOLD) is developing costly gene therapies for rare diseases, which requires significant capital expenditures. The book value per share, calculated under US GAAP as the difference between assets and liabilities per share, determines the intrinsic value of the business. The current BVPS stands at 0.88, reflecting the company's actual equity. The trend of this metric allows for an assessment of asset quality beyond market euphoria. Growth in this metric confirms financial stability during expansion within the orphan drug segment.